Cytori Therapeutics (NASDAQ: CYTX) reported Q1 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $2.9 million versus the consensus estimate of $2.05 million.

Q1 2016 operating cash burn of $5.1 million, compared to $5.0 million for the same period in 2015. Cash and debt principal balances at March 31, 2016 of approximately $9.4 million and $17.7 million, respectively.

“The business fundamentals continue to strengthen,” said Dr. Marc H. Hedrick, President and CEO of Cytori Therapeutics. “The US trial enrollment for our lead indication is nearly complete, we see positive trends on revenue and we continue see new opportunities for our technology that are in alignment with the Company’s core strategic direction.”

For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.